Acurx Pharmaceuticals, Inc.
For the period ended Dec 31, 2024. Filed Mar 17, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 17, 2025
ACXP$1.060.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations
| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | Years Ended | ||||||
| · · · December 31, | |||||||
| · 2024 · 2023 | |||||||
| | | | | | | | |
| OPERATING EXPENSES · · | |||||||
| Research and Development | | | $5,403,836 | | $6,043,597 | ||
| General and Administrative | | | 8,699,267 | | 8,534,171 | ||
| | | | | | | | |
| TOTAL OPERATING EXPENSES | | | 14,103,103 | | 14,577,768 | ||
| | | | | | | | |
| NET LOSS | | | $(14,103,103) | | $(14,577,768) | ||
| | | | | | | | |
| LOSS PER SHARE | | | | ||||
| Basic and diluted net loss per common share | | | $(0.87) | | $(1.15) | ||
| | | | | | | | |
| Weighted average common shares outstanding, basic and diluted | | | 16,163,366 | | 12,671,572 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.